Cisatracurium Besylate Injection
Product Images NDC 55150-284

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Cisatracurium Besylate (NDC 55150-284). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eugia Us Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1. Maximum Percent Change From Preinjection In Hr And Map During First 5 Minutes After Initial 4 × Ed95 To 8 × Ed95 Cisatracurium Doses In Healthy Adults Who Received Opioid/nitrous Oxide/oxygen Anesthesia (n = 44) (Cisatracurium Fig1)

The text is not available as it lacks context and does not form a coherent description.*

FDA Label Image

Figure 2. Percent Change From Preinjection In Hr And Map 10 Minutes After An Initial 4 × Ed95 To 8 × Ed95 Cisatracurium Dose In Patients Undergoing Cabg Surgery Receiving Oxygen/fentanyl/midazolam/anesthesia (n = 54) (Cisatracurium Fig2)

The given text is describing a table or a graph with three rows and two columns displaying an alternating pattern of two percentages, +60% and -60% against the heading "HR". It is not clear what the chart represents or what the percentages denote.*

FDA Label Image

Package Label-principal Display Panel (20 mg per 10 mL (2 mg per mL))

This is a warning label for a drug called Cisatracurium Besylate Injection, which contains a paralyzing agent that can cause respiratory arrest. Facilities must be available for artificial respiration. The drug should be stored at 2°-8°C and protected from light. It comes in a multiple-dose vial and contains benzyl alcohol as a preservative. The label also provides information on the manufacturer and distributor of the drug.*

FDA Label Image

Package Label-principal Display Panel (20 mg per 10 mL (2 mg per mL))

This is a package insert for an intravenous injection medication called Cisatracurium besylate, containing 20mg per 10mL (2mg per mL) of the active ingredient. The medication is a paralyzing agent and also contains benzyl alcohol as a preservative. The injection is intended for use as an anesthetic during certain medical procedures. It must be stored at a temperature between 2°C and 8°C and must not be frozen. The dosage should follow the instructions provided in the package insert. The medication is distributed by AuroMedics Pharma LLC and is made in India.*

FDA Label Image

Package Label-principal Display Panel (2 mg/mL)

This is a label of Cisatracurium Besylate Injection, USP which shows the strength of the injection in mg/mL. It also gives instructions to peel off and apply to syringe b. Additionally, it provides information on the date and time of manufacture or processing, which is Dt Tm: By: P1416958.*

FDA Label Image

Chemical Structure (Cisatracurium Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.